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Abstract: Wound care has been clinically demanding due to inefficacious treatment that represents an
economic burden for healthcare systems. In Europe, approximately 7 million people are diagnosed
with untreated wounds, leading to a cost between 6.000€ and 10.000€ per patient/year. In the United
States of America, 1.5 million people over 65 years old suffer from chronic wounds. A promising
therapeutic strategy is the use of exogenous growth factors because they are decreased at the wound
site, limiting the recovery of the skin. Insulin is one of the cheapest growth factors in the market
able to accelerate the re-epithelialization and stimulate angiogenesis and cell migration. However,
the effectiveness of topical insulin in wound healing is hampered by the proteases in the wound
bed. The encapsulation into nanoparticles improves its stability in the wound, providing adhesion
to the mucosal surface and allowing its sustained release. The aim of this review is to perform a
standing point about a promising strategy to treat different types of wounds by the topical delivery
of insulin-loaded nanocarriers.
Keywords: insulin; wound healing; nanomedicine; topical delivery; wounds; burns; polymer
nanoparticle; lipid nanoparticle; inorganic nanoparticle
1. Introduction
Wound healing is a biological and dynamic process, in which the skin begins to self-
repair after an injury. The prevalence of wounds has been increasing, becoming a significant
public health issue with high morbidity and mortality rates among the population. About
100 million people across the globe suffer from acute wounds and 300 million from chronic
wounds, representing a major cost for health-care systems. Populations with high-risk of
incidence of chronic wounds, such as diabetics, obese, and elderly people, have a high
probability of experiencing it during their lifetime [1]. While the treatment of acute and
superficial wounds is highly efficacious, treating chronic wounds is challenging [2]. The
approach for chronic wound healing has been in reducing the inflammation and topical
application of exogenous growth factors. However, ongoing therapies lack efficacy, leading
to long-term recovery due to excessive proteases at the wound site [3]. Insulin, a peptide
hormone used in diabetic patients to manage blood glucose levels is also used as a growth
factor, being able to mitigate the compromised skin by triggering cell migration and
proliferation in order to coalesce and heal the wound. Insulin stimulates the migration of
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keratinocytes, influences the proliferation of fibroblasts and the production of extracellular
matrix proteins, and modulates the release of inflammatory cytokines [4]. Moreover, insulin
is also a low-cost growth factor and a compatible wound dressing, turning the inclusion of
this peptide hormone into dressing matrices beneficial for wound treatment efficacy [5].
Despite the benefits of insulin in wound healing, its lack of stability in the wound
bed due to the proteases action hampers its therapeutic benefits. In past years, research
in the field of nanomedicine has progressed toward improving nanomaterials features,
such as large surface area to volume ratio, antimicrobial activity, or electric conductivity of
small-scale particles. Many biological processes occur in the nanometer range, causing the
nanoparticles (NPs) to be singular instruments for drug delivery [6]. Thus, the encapsu-
lation of insulin into nanoparticles is an excellent strategy to improve the stability of the
protein in the wound bed and deliver it in a controlled manner, improving the therapeutic
outcome. Different materials have been explored to produce insulin-loaded nanocarriers,
mainly from lipid, polymer, or inorganic sources.
The main aim of this review is to address the benefits of nanocarrier-mediated topical
insulin delivery as a promising strategy for wound healing applications. Herein, the effect
of insulin in wound healing and the advantages of its encapsulation into nanocarriers
are addressed. More importantly, the different types of nanocarriers used to deliver
insulin topically as well as their in vitro and in vivo performance will be discussed. Finally,
pipeline products for growth factors delivery and toxicity concerns are regarded. It is
expected that this contribution may be a good starting point to future research works in
the field.
2. Anatomophysiology of Skin
2.1. Healthy Skin
The skin is the largest organ of the body, covering its whole surface with a surface
area between 1.5–2.0 m2 of an average adult [4]. The skin, composed of epidermis, der-
mis, and hypodermis (Figure 1), is a vital barrier between the environment and the body
against pathogens, lesions, loss of water and heat, capable of offering sensory perception
and immune protection [5]. The primary barrier of the skin is in the upper layer, namely
the stratum corneum. The stratum corneum is formed by corneocytes or terminally dif-
ferentiated keratinocytes inserted in the extracellular lipid matrix formed by ceramides,
cholesterol, and fatty acids. Underlying the stratum corneum are the stratum granulosum,
stratum spinosum, and stratum basale from the epidermis [7]. The stratum corneum
building blocks, keratinocytes, are influenced by cytokines, which play key roles for inflam-
matory processes, including cell signaling, consenting cell secretion, division, migration,
growth and repair. Also present in the epidermis are the Langerhans cells, which are
formed in the bone marrow [8].
Underlying the epidermis is the dermis consisting of two sublayers: the reticular
dermis and the papillary dermis. The reticular dermis is composed of connective tissue
proteins and a vascular network. The papillary dermis is composed of capillary loops
essential for oxygenation and nutrient supply, sebaceous glands, sweat glands, nerves, and
hair follicles [9]. The cells in the dermis are fibroblasts, mast cells, histiocytes, adipocytes,
and macrophages [10]. Gay et al. showed that fibroblasts stimulate type I collagen synthesis,
offering support to the skin [11]. In 2005, Lee & Cho demonstrated interactions between
skin fibroblasts and human epidermal keratinocytes by increasing the expression of type
IV collagen, type VII collagen, and laminin [12]. Finally, the hypodermis is located at the
bottom layer of the skin, between the dermis and the muscle. The hypodermis is composed
of connective tissue, blood vessels, nerves and adipocytes, serving as the body energy
reserve and protection against mechanical injury of the body from mechanical injuries [13].
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Figure 1. Histological structure of skin. 
2.2. Skin Wounds 
The wound is a consequence of an intentional, accidental, or disease process causing 
damage to the skin barrier [14]. Wound healing is a well-ordered and multi-stage process 
in which different cells interact with the extracellular matrix (ECM) to promote skin re-
generation. Upon injury, cytokines are released, and hemostasis begins, progressing to the 
phases of inflammation, proliferation, and remodeling (Figure 2) [15]. After completing 
hemostasis and preventing the blood hemorrhage, the inflammation process occurs. Ar-
teriolar constriction causes a decrease in blood flow, leading to a reflex vasodilatation and 
relaxation of the arterial vessels. The inflammatory response contributes to the onset of 
prostaglandin synthesis, which results in local vasodilation. Mast cells release histamine 
to increase vasodilatation and vascular permeability, facilitating the movement of inflam-
matory cells and proteins into the extracellular space around the wound [16]. Other in-
flammatory mediators such as kinin and serotonin are released, boosting microvascular 
permeability. The proliferative phase is characterized by the proliferation of fibroblasts 
and collagen deposition. A new matrix will be composed of fibronectins, proteoglycans, 
and collagen. The angiogenesis process begins, followed by the proliferation of epithelial 
cells and the formation of new connective tissue and blood vessels in the wound bed. 
Macrophages and platelets secrete platelet-derived growth factor (PDGF), which induces 
fibroblast proliferation and chemotaxis. Fibroblasts migrate to the wound and move 
through the extracellular matrix, linking fibrin, vitronectin, and fibronectin, via an argi-
nine-glycine-aspartic acid amino acid sequence. Furthermore, fibroblasts produce matrix 
metalloproteinases (MMPs), which remove impaired matrix components and enable fi-
broblast movement. Tumor necrosis factor-alpha (TNF-α) and basic fibroblast growth fac-
tor (bFGF) activate endothelial cells to initiate angiogenesis. Angiogenesis is the physio-
logical process that allows the formation of new blood vessels to replace the damaged 
capillaries, providing adequate oxygen and nutrients to the wound area. Low oxygen lev-
els, low pH, and high lactate levels also stimulate the vascularization process [17]. The 
final phase of wound healing is the remodeling phase, in which novel epithelium is de-
veloped together with scar formation. In acute wounds, the levels of collagen increases, 
promoting wound tensile strength [18]. Regular collagen formation and disintegration, as 
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whic differ nt cells interact with the ext l r atrix (ECM) to promote skin regenera-
tio . Upon injury, cytokines are releas d, and hemostasis begins, r r ssi g to the phases
of inflammation, proliferation, and remodeling (Figure 2) [15]. After completing hemostasis
and preventing the blood hemorrhage, the inflammation process occurs. Arteriolar con-
striction causes a decrease in blood flow, leading to a reflex vasodilatation and relaxation
of the arterial vessels. The inflammatory response contributes to the onset of prostaglandin
synthesis, which results in local vasodilation. Mast cells release histamine to increase
vasodilatation and vascular permeability, facilitating the movement of inflammatory cells
and proteins into the extracellular space around the wound [16]. Other inflammatory
mediators suc as kinin and serotonin are released, boosting microvascular permeability.
The proliferative phase is char cterized by the proliferati of fibroblasts and collagen
deposition. A new matrix will be compo ed of fibronectins, proteoglycans, and collagen.
The a giogenesis process begins, followed by the pr liferation of epithelial c lls and the
formation of new connective tissue and blood vessels in the wound bed. Macrophages and
platelets secrete platelet-derived growth factor (PDGF), which induces fibroblast prolifera-
tion and chemotaxis. Fibroblasts migrate to the wound and move through the extracellular
matrix, linking fibrin, vitronectin, and fibronectin, via an arginine-glycine-aspartic acid
amino acid sequence. Furthermore, fibroblasts produce matrix metalloproteinases (MMPs),
which remove impaired matrix components and enable fibroblast movement. Tumor necro-
sis factor-alpha (TNF-α) and basic fibroblast growth factor (bFGF) activate endothelial
cells to initiate angiogenesis. Angiogenesis is the physiological process that allows the
formation of ew blood v ssels to replace th dam ged capillaries, providing adequate
oxygen and nutrients to the wound ar a. Low oxygen levels, low pH, and high lactate
levels als s imulate the vascularization process [17]. Th final phase of wound healing is
the remodeling phase, in which novel epithelium is developed together with scar formation.
In acute wounds, the levels of collagen increases, promoting wound tensile strength [18].
Regular collagen formation and disintegration, as well as remodeling of the extracellular
matrix, are completed within 3 weeks of trauma until a steady shape is reached. The ap-
proximation of the wound edges and the connective tissue size reduction is a consequence
of the interactions between the extracellular matrix and the fibroblasts.
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flammation is stagnant or devitalized tissue is surgically removed, the therapy for chronic 
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Figure 2. Stages of wound healing of skin.
Overall, the process of wound healing consists of three key mechanisms: set of
granulation tissue, contraction, and epithelialization. Depending on the type of wound,
these three mechanisms act in different ways. Chronic wounds, namely pressure ulcers,
diabetic ulcers, and venous ulcers, are wounds that have a prolonged inflammation and
do not heal ithin 12 weeks (Table 1) [19]. These wounds have high levels of MMPs, an
increase of inflammato y cytokines release, debris, and infection [20]. As the microbial
l ad on the wound expa ds, healing is considerably interrupted. Th inflammatory
respon e releases an excess amou t of reactive oxygen species and i flammatory cytokines,
leading to cont uous state of inflammation and proteolytic enzymes. Increased levels
of proteas in the wound result in the deterioration of local proteins such as extracellular
matrix proteins and growth factors, matrix component reduction, epithelialization process
disturbance, and wound contraction failure [21,22]. Thus, chronic wounds are characterized
by excessive inflammation, hypoxia, high biological bioburden, prolonged protease activity,
neuropathy and, in cases of irreparable tissue damage, fibrosis. Essentially, once chronic
inflammation is stagnant or devitalized tissue is surgically removed, the therapy for chronic
wounds prevents infection and promotes healing in the same way as the acute wounds [23].
Table 1. Types of chronic wounds and its main features.
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2.3. Burns
A burn is defined as a coagulative destruction of the skin and can be superficial
or thick with moderate to heavy extension. Partially thick burn wounds typically form
epithelial cell coverage over a period of no more than 20 days, whereas full-thickness burn
wounds may require the removal of damaged and dead tissue to improve healing [32].
Thermal damage, radiation, electricity, and chemicals can cause burns. Skin recovery
and various manifestations such as respiratory failure, infection, shock, or electrolyte
variation are based on body area and burn depth. The burn extent is expressed as a
percentage of the total body surface area (% TBSA) [33]. Burns present high mortality and
morbidity levels. In the United States, burns are the seventh leading cause of death from all
unintentional injuries [34]. Burn treatment costs are around USD 7.5 billion/year, adding
treatment for infection, inflammation, and ischemia [35]. Each year in the United Kingdom,
approximately 250.000 people attend hospitals due to burns [36]. Burns are categorized
into four types, depending on the depth of the dermal lesion (Figure 3). First-degree
burns involve damage to the superficial epidermis and manifest redness, dryness, and
hypersensitivity. In second-degree burns, there is complete elimination of the epidermis
and partial dermal loss. The skin turns red and edematous with blisters. Third-degree
burns are full-thickness burns that reach the hypodermis. Full-thickness burns are, in
most cases, painless, as a result of nerve damage [33]. Finally, fourth-degree burns are
burns extended up to the bone or muscle. Overall, the efficacy of treatment relies on its
extent [37].




Figure 3. First to third degrees of burn wounds in human skin. 
Increased capillary permeability induced by burns leads to leakage of small protein 
molecules and edema [38]. The inflammatory response is triggered, activating the synthe-
sis of inflammatory mediators, such as prostaglandins, leukotrienes, tumor necrosis factor 
(TNF), nitric oxide, or histamine. In an early stage, histamine induces the venules to con-
tract and microvascular permeability. Burned patients have shown inhibition of insulin 
release, stimulation of cortisol release, proteolysis, and gluconeogenesis [39]. 
3. Effect of Insulin in Wound Healing 
3.1. Diabetic Wounds 
Patients suffering from diabetes mellitus manifest several complications such as 
nephropathy, neuropathy, or retinopathy. In wound healing, cell migration, growth and 
differentiation are also absent among diabetic patients. The low levels of growth factors, 
fibroblast dysfunction, increased proteolytic activity, and impairment in collagen assem-
bly are manifested in diabetic wounds. Moreover, diabetic patients show increased levels 
of TNF-α and IL-6, leading to severe inflammation and insulin resistance [40,41]. 
Peripheral neuropathy causes chronic wounds in the limbs, commonly referred to as 
diabetic foot ulcer, lower extremity arterial disease, and foot deformity [42]. It is prevalent 
in about 7% of diabetic patients and is more recurrent among the elderly. Diabetic foot 
ulcer care involves a multifaceted procedure, consisting of surgical removal of the necrotic 
tissue, prevention or treatment of infections, limb elevation, and compression as well as 
revascularization [43]. 
In 1923, William Thalhimer was the first to describe the insulin activity in postoper-
ative acidosis [44]. In parallel, Foster showed improvement in postoperative recovery 
among 20 diabetic patients receiving between 30 and 75 of insulin units intravenously. 
Wound healing among the diabetic patients was ameliorated and the number of deaths 
due to infection decreased approximately 30% in type I diabetic patients [45]. In a case 
study in 1965, a 56-year-old woman with diabetes was amputated below her knee due to 
gangrene on her foot and leg. The amputated stump became infected with Streptococcus 
pyogenes. She was administrated both cloxacillin and erythromycin, yet no improvement 
was observed. Thus, the researchers topically administered 20 IU of soluble insulin in 
gauze covered by a bandage, changing it twice a day. Four days later, the mitigation of 
the bacterial infection was observed [43]. Weringer tested the influence of insulin on 
wound recovery using diabetic and non-diabetic C57B1/6 mice treated and non-treated 
with insulin. The mice ears were perforated with a 0.1 cm dermal trephine and insulin 
was administered 40 h later. The ear wounds were evaluated by light and electron micros-
copy and fibroblasts, capillaries, polymorphonuclear leukocytes (PMN), collagen, and in-
terstitial oedema were quantified by lineal point analysis. The untreated diabetic mice 
showed reduced capillaries, fibroblasts, collagen and PMN of total percent wound vol-
ume, in contrast to the similar response of both insulin-treated diabetic mice and control 
mice. The total percent wound volume for oedema was 44.0 ± 1.2% in the case of untreated 
Increased capillary per eability induced by burns leads to leakage of s all protein
olecules and ede a [38]. The infla atory response is triggered, activating the synthesis
of inflammatory mediators, such as prostaglandins, leukotrienes, tumor necrosis factor
(TNF), nitric oxide, or histamine. In an early stage, histamine induces the venules to
contract and microvascular permeability. Burned patients have shown inhibition of insulin
release, stimulation of cortisol release, proteolysis, and gluconeogenesis [39].
3. Effect of Insulin in Wound Healing
3.1. Diabetic Wounds
Patients suffering from diabetes mellitus manifest several complications such as
nephropathy, neuropathy, or retinopathy. In wound healing, cell migration, growth and
differentiation are also absent among diabetic patients. The low levels of growth factors,
fibroblast dysfunction, increased proteolytic activity, and impairment in collagen assembly
are manifested in diabetic wounds. Moreover, diabetic patients show increased levels of
TNF-α and IL-6, leading to severe inflammation and insulin resistance [40,41].
Peripheral neuropathy causes chronic wounds in the limbs, commonly referred to as
diabetic foot ulcer, lower extremity arterial disease, and foot deformity [42]. It is prevalent
in about 7% of diabetic patients and is more recurrent among the elderly. Diabetic foot
ulcer care involves a multifaceted procedure, consisting of surgical removal of the necr tic
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tissue, prevention or treatment of infections, limb elevation, and compression as well as
revascularization [43].
In 1923, William Thalhimer was the first to describe the insulin activity in postoperative
acidosis [44]. In parallel, Foster showed improvement in postoperative recovery among
20 diabetic patients receiving between 30 and 75 of insulin units intravenously. Wound
healing among the diabetic patients was ameliorated and the number of deaths due to
infection decreased approximately 30% in type I diabetic patients [45]. In a case study in
1965, a 56-year-old woman with diabetes was amputated below her knee due to gangrene
on her foot and leg. The amputated stump became infected with Streptococcus pyogenes. She
was administrated both cloxacillin and erythromycin, yet no improvement was observed.
Thus, the researchers topically administered 20 IU of soluble insulin in gauze covered by a
bandage, changing it twice a day. Four days later, the mitigation of the bacterial infection
was observed [43]. Weringer tested the influence of insulin on wound recovery using
diabetic and non-diabetic C57B1/6 mice treated and non-treated with insulin. The mice
ears were perforated with a 0.1 cm dermal trephine and insulin was administered 40 h
later. The ear wounds were evaluated by light and electron microscopy and fibroblasts,
capillaries, polymorphonuclear leukocytes (PMN), collagen, and interstitial oedema were
quantified by lineal point analysis. The untreated diabetic mice showed reduced capillaries,
fibroblasts, collagen and PMN of total percent wound volume, in contrast to the similar
response of both insulin-treated diabetic mice and control mice. The total percent wound
volume for oedema was 44.0 ± 1.2% in the case of untreated diabetic mice, while insulin
treated diabetic mice and control showed 13.5% ± 0.7 and 10.5 ± 1.3%, respectively. These
results show that insulin treatment induced neovascularization, fibroblast proliferation,
synthesis of collagen, and edema reduction in diabetic rats compared to placebo-treated
diabetic and healthy rats [46].
Insulin pathways activation were analyzed in rats and diabetic patients with the
administration of topical insulin cream [47]. The study compared male Wistar induced
diabetic rats treated with and without topical insulin cream, along with non-diabetic rats.
Wounds of diabetic rats were treated with 0.5 U/100 g of insulin cream or placebo, applied
directly after skin excision and then every day until the end of the study. The authors
observed an abrupt cellular response in diabetic animals and faster wound healing concomi-
tant with an increase of protein levels, such as nitric oxide synthase (NOS) and vascular
endothelial growth factor (VEGF), than the wounded tissue of normal rats. Conversely, the
expression of insulin receptor substrate (IRS), protein kinase B (AKT), and extracellular
signal–regulated kinases (ERK) was reduced in the wounded skin of diabetic rats, com-
pared to the wounded skin of normal rats, indicating an increase of wound recovery period.
Immunoblotting results showed approximately 25% of IRS-1 protein levels in the wounded
skin of diabetic rats, in contrast to 270% of IRS-1 in the wounded skin of normal rats. AKT
levels were approximately 50% less in the wounded skin of diabetic rats compared to the
wounded skin of normal rats. The extracellular signal-regulated kinase (ERK) pathway
was stimulated in the wound healing tissue on healthy rats, in contrast with undamaged
skin, which highlights the major contribution that insulin signal transduction occupies in
wound healing. In the clinical study, 22 diabetic patients with uncured lacerations for at
least 3 months were randomized to assess the effect of topical insulin in a double-blind,
placebo-controlled clinical trial for 8 weeks. Changes in the laceration length, width, and
depth were observed. After 8 weeks, the patients that received the insulin cream showed
a significant recovery in contrast to the patients that received the placebo cream. The
treatment using insulin cream continued for both groups, and by the week 15, all patients
showed total recovery.
Li and co-workers proposed an effective topical insulin delivery system to protect
the insulin’s vulnerable structure by encapsulation into microparticles. Later, insulin
microparticles were incorporated in a silk fibroin sponge. The authors were able to maintain
the molecular structure of insulin and an extended release for 30 days. Moreover, the
in vivo restorative effect of the matrix wound dressing was assessed in full-thickness
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diabetic wounds of Sprague-Dawley rats. After 3 weeks, histological analyses revealed
strong cell relocation, collagen deposition, and epidermis, compared to control [48]. Ribeiro
et al. prepared chitosan nanoparticles loaded with insulin embedded in a hydrogel and
evaluated their therapeutic activity for wound healing in diabetic rats. The chitosan
nanoparticles had a size below 200 nm, a positive potential zeta (33.7 ± 4.88 mV), and an
AE of approximately 97%. In vivo studies showed the emergence of large blood vessels
at day 7 for the animals treated with insulin-chitosan nanoparticles, although, empty and
insulin-loaded chitosan nanoparticles were able to stimulate inflammatory cell proliferation
and angiogenesis.
3.2. Non-Diabetic Wounds
Non-diabetic wounds are caused by trauma, pressure, inflammation, or cardiovascu-
lar disease without a diabetic origin. In comparison with diabetic wounds, non-diabetic
wounds have shown less recurrence, lower incidence of infections, and less wound appear-
ance in the lower limbs [49].
In 1930, the Barnet Joseph published a brief communication describing the effect of
10 IU of insulin administered once daily in five patients suffering from non-diabetic pres-
sure ulcers. After 14 days, considerable improvement was observed in skin recovery [50].
Rosenthal, in 1968, used albino Wistar rats to evaluate the stimulation of wound healing
caused by insulin. A laceration was performed on the abdomen of rats, and suspensions
of protamine-zinc insulin were administered 3 days before the incision and every day
thereafter. Insulin-treated animals expressed an increase in body weight and, in parallel, a
20% increase in skin toughness at the wound site [43].
Udupa and colleagues studied the histological aspects of insulin in skin wounds in
rats. Albino rats, having an average weight of 110 g, were given 0.02 units of protamine
zinc insulin per g bodyweight subcutaneously once per day through a period of 3 weeks.
The trial was composed of 25 insulin-treated rats and 25 controls. Incision wounds in the
abdominal of 50 mm in length were sutured with cotton stitches and the effects of wound
reopening were observed. The insulin treated rats showed increased wound bursting
strength in contrast to the control group, demonstrating a significant difference in the 7th
and 12th days (p < 0.01). Histological evaluation showed accelerated collagen production
and higher collagen structure organization, compared to the control group [51]. Additional
studies observed the positive effect of insulin on wound recovery. Wilson and co-workers
reported an 80-year-old patient suffering from a chronic postoperative abdominal wall
wound who underwent negative-pressure wound therapy (NPWT) to improve wound
closure, re-epithelialization, and humidity by promoting granulation tissue formation.
However, after 21 days of NPWT, the chronic postoperative wound did not heal. The
wound was washed with 2 IU/20 mL of human soluble insulin every day for 1 week. There
was also no evidence of side effects regarding the use of insulin solution [52].
Zhang et al. (2007) questioned the efficacy of local insulin application in contrast
with intravenous therapy concerning wound-healing rate, dropping of blood sugar, and
potassium levels, as these signs appear in intravenous insulin administration. Insulin-zinc
solution was injected locally around the wound and every other day into white male New
Zealand rabbits. The authors noticed a higher healing rate among animals with localized
insulin therapy compared to intravenous treatment cohorts [53]. Two years later, Liu et al.
also studied the influence of insulin on keratinocyte migration and on PI3K-AKT signal
transduction pathway activation in non-diabetic wounds. An in vitro study scratch assay
was performed in cultured human keratinocytes, in which insulin treatment stimulated
human keratinocyte migration and differentiation. The immunoblot test showed increased
AKT activation levels after insulin application for at least 1 h. Furthermore, the in vivo
study was composed of C57BL/6J mice with a 0.7 cm punch excision wound. Insulin was
topically administered and animal lacerations exhibited a significant epithelium restoration
compared to the control group [54].
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3.3. Burns
The pathophysiology of burns differs from the biological mechanism for healing
incisional and excisional wounds. The frequency of episodes of hyperglycemia and insulin
resistance has been observed in patients with severe burns, decreasing the probability
of wound healing. Studies have been conducted to obtain more information about the
chemical processes involved during burning and on the effectiveness of its treatment with
insulin [55]. In 1995, Sakurai et al. administered insulin intravenously to nine patients
suffering from severe burns for 1 week to assess the variation in muscle protein levels. The
novel amino acids production, their relocation from the blood, and a significant increase
in muscle mass was observed due to the presence of insulin. Although the results were
variable among patients, the authors observed that insulin treatment caused an increase
of nearly 50% in protein synthesis at the wound site [56]. Later, in 1999, Zhang and
collaborators considered the effect of insulin and growth hormone on protein synthesis in
muscle and wounds. L-[ring-13C6]phenylalanine was used to determine protein anabolism.
Rabbits which had undergone thermal ear burns were randomly divided into four groups:
growth hormone, high-dose insulin, low-dose insulin, and blank control groups. Both high
and low doses of insulin significantly decreased protein breakdown (p < 0.01), stimulating
protein synthesis and inhibiting proteolysis, compared to the growth hormone group in
which there was no change in protein balance [57]. Zhang and collaborators analyzed the
protein levels in partial-thickness wounds through the introduction of insulin and several
amino acids. Male New Zealand White rabbit ears were subjected to 72 ◦C water for 3 s.
The scalded ears were used as an arteriovenous unit to measure the response of protein
kinetics in the wound. The authors found increased wound protein production with both
an exogenous amino acid mixture and high dose of insulin infusion administration, moving
from 7 ± 4 µmol.100 g−1.h−1 to 1 ± 5 µmol.100 g−1.h−1 in the control group [58].
In 2001, Van den Berghe and co-workers evaluated the recovery rate of patients who
received insulin at the surgical intensive care unit for one year. The authors conducted a
prospective, randomized, controlled clinical trial where patients with assisted ventilation
were divided into two groups. One group received a common insulin infusion therapy
while the other experienced exhaustive insulin treatment. In the common insulin infusion
group, glycemia was kept between 180 and 200 mg/dL, and insulin was only administered
if the blood glucose level passed 215 mg/dL. In the exhaustive insulin therapy group, the
glycemia was kept between 80 and 110 mg/dL. The authors verified that exhaustive insulin
infusion reduced mortality by 8%, in contrast to 4.5% mortality reduction in the common
insulin infusion group. Furthermore, patients who received exhaustive insulin treatment
did not need extended assisted ventilation [59]. It has been suggested that severe burns
cause insulin resistance along with impaired insulin signal. Following a severe burn, an
acute phase reaction occurs in the liver, stimulating an inflammatory response and the
immune system. In 2007, Jeschke et al. studied the impact of insulin therapy on severely
burned hepatic-failure patients. The researchers observed improvement in liver function
in burned patients treated with insulin by finding reduced levels of transcription factors
and inflammatory cytokines. Insulin therapy increased recovery chances by minimizing
sepsis in critically burned patients [60]. In 2010, Jeschke and collaborators explored the
consequence of insulin administration on death rates in severely burned pediatric patients
having burns above 30% of TBSA. The mortality rate for the control group was 11%,
whereas the mortality rate for the pediatric insulin patients group was lower by 7% [61].
In 2012, Jeschke et al. developed a clinical study in severely burned children over
15 months to estimate the correlation between hyperglycemia and insulin resistance within
unfolded protein response (UPR). UPR is a cellular stress response associated with endo-
plasmic reticulum (ER) stress. Researchers concluded that during patient rehabilitation,
biochemical processes linked to the cell cycle, swelling, sarcoplasmic reticulum stress,
and insulin resistance were altered [62]. Later, in 2013, Vural’s team examined the link
between insulin and liver. The study was developed in severely burned patients who
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were receiving insulin. The authors found increased prealbumin and albumin levels, and
decreased triglycerides and pro-inflammatory proteins levels with insulin therapy [63].
In 2010, Fram and co-workers found that insulin administration was safe and effi-
cient in pediatric burn patients due to decrease of insulin resistance and improvement
of metabolic hemostasis. A randomized clinical trial was conducted in burned pediatric
patients whose burns exceeded 40% of TBSA. Two groups were created: conventional
insulin treatment and intensive insulin treatment. The patients in the first group received
an average insulin concentration of 55 µU/mL and had their blood glucose values below
215 mg/dL, while the second group received 105 µU/mL of insulin and had their blood
glucose values between 80 and 110 mg/dL. Reduction of hepatic glucose secretion was
lower in the conventional insulin treatment, in contrast to intensive insulin treatment, being
2.5 ± 0.6 vs. 5.0 ± 0.9 mg/kg·min, respectively. Intensive insulin treatment significantly
improved mitochondrial oxidation of palmitate [64]. Tuvdendorj et al. performed skin
transplants on burned children with more than 40% TBSA and examined the effect of
insulin on the accelerating healing rate. In the first days after surgery, the authors observed
an increase in the fractional synthetic rate (FSR) of the donor site wound protein, leading
to increased collagen and laminin levels [65].
Azevedo et al. (2015) studied the effects of topical insulin application on wound
healing in rats subjected to second-degree burns on the increase of collagen retention,
stimulation of the microvascular network, and depression of the inflammatory phase.
The animals were divided into four groups: diabetic rats receiving topical insulin cream,
diabetic rats receiving placebo, healthy rats receiving topical insulin cream, and healthy
rats receiving placebo. Histological examination showed increased Type III collagen levels
between days 1 and 7 in healthy and diabetic wounds treated with insulin cream, compared
to diabetic wounds treated with placebo. Angiogenesis and inflammatory responses were
significantly higher at 2 weeks postburn in wounds treated with insulin cream to levels
related to those of healthy rats receiving topical insulin cream and placebo [66]. Dhall et al.
improved insulin stability required for wound healing by developing an alginate dressing
containing insulin encapsulated in PLGA microparticles and showing sustained release for
more than 3 weeks. The in vivo study was performed on the dorsum of Sprague–Dawley
rats that had partial-thickness burn wounds made with a 15 mm diameter brass cylinder
warmed up to 80 ◦C. Alginate dressings having 0.04 mg insulin/cm2 were then applied
once every 3 days for 9 days, promoting higher levels of neutrophils and M1 macrophages.
Histological examination showed increased collagen levels with fibers deposited neatly on
the skin and a lower rate of necrotic tissue [35].
4. Advantages of Nanocarriers for Topical Insulin Delivery
The topical administration of growth factors in chronic wounds, such as epidermal
growth factor or platelet-derived growth factor, have shown favorable results in skin
regeneration [67]. The degradation of growth factors in the wound bed is rapid and the
length of time required for growth factors to react with the cells is not yet known [68].
Nanocarriers are small drug delivery systems in form of micelles, liposomes, and
nanoparticles based on biological or synthetic materials that are vehicles for drugs offering
protection against degradation. Growth factors are often unstable biomolecules, susceptible
to temperature, light or ionic strength changes, leading to denaturation, and reduced
biological activity [69]. Insulin is one of the cheapest growth factors available on the
market, but its topical therapeutic use has been associated with a short half-life in vivo due
to proteases in the wound bed. Hence, insulin encapsulation ensures proteolysis prevention,
maintaining the amino acid chain and the three-dimensional protein arrangement [70]. The
physicochemical properties of nanoparticles, such as size and association efficiency (AE),
can be tailored, and nanoparticles features can be tuned to increase drug bioavailability and
to modify the biological action [71]. In addition of presenting biocompatibility, bioadhesion,
swelling, and antimicrobial activity characteristics, the nanoparticles are versatile to vast
product applications, suitable for a material for wound healing [23]. Their small size
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and increased surface area offer occlusive properties and a moisturizing effect, as well as
intracellular entry and a transfer facility throughout the skin layers [72]. The nanoparticles’
capacity to provide a controlled and sustained release, avoiding the need for a frequent
administration, also allow the administration of lower doses, proving to be a valuable
strategy for chronic wound treatment [70]. Overall, the encapsulation of insulin is an
excellent approach to avoid rapid clearance and improve wound healing [73].
5. Nanocarrier Systems for Topical Insulin Delivery
Insulin has shown promising results for cutaneous wound care, but its low stability in
the wound bed is an important drawback. Thus, its encapsulation into nanocarriers has
been suggested as a promising strategy [74]. A small amount of studies addressing the use
of insulin-loaded nanocarriers for wound healing applications are reported. In this section,
the different types of nanoparticles (Figure 4) under consideration for topical delivery of
insulin are described. They are mostly from lipid, polymer, or inorganic origin, and are
briefly summarized in Table 2.
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5.1. Lipid-Based Nanoparticles
Lipid-based nanoparticles, including liposomes, solid lipid nanoparticles (SLN) and
nanostructured lipid carriers (NLC) have been widely used for topical application due to
their ability to release drugs in a sustained manner, displaying high tolerance, adequate
skin absorption, and epidermal drug accumulation [75].
5. .1. Lip somes
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tion. They are formed by t least two lipophilic layers, which can load hydrophobic and
hydrophilic drugs, with a dimension usually between 100 and 1000 nm [76]. Liposomes
are typically composed of phospholipids consisting of a polar head and two nonpolar
chains. Because of their amphipathic features, when in contact with water membranes,
hydrophilic heads interact with the aqueous solution and hydrophobic tails interact with
each other [77]. Hydrophilic drugs may be incorporated into the interior domain of the
liposome, including genetic material for delivery of non-viral gene vectors, avoiding viral
particle toxicity [78]. Hydrophobic active ingredients may be integrated into the coupled
lipid layer, while ligands may be attached to the outer layer. The incorporation of polyethy-
lene glycol (PEG) into the outer layer of the liposome pr vides protection from rapid
degradation and allows sustained and controlled release [79]. Due to th presence of lipid
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bilayers that mimic the cell membrane of the human body, liposomes have been extensively
used for topical drug administration [80]. Wound dressings made of non-woven gauzes
impregnated with liposomes have been used showing drug release and more accurate
management of chronic topical inflammation [81]. Conversely, liposomes have revealed
poor long-term stability leading to reduced encapsulation efficiency, low reproducibility,
heterogeneous size distribution, and sudden and uncontrolled drug release during stor-
age [82]. Liposomes can easily sediment, aggregate, lose shape when intensely shaken
or pressed, and accumulate under the continuous skin administration as the epidermal
clearance of the drug is slower [83].
Dawoud and co-workers (2018) prepared insulin-loaded liposomes by employing
various lipids and incorporating them into a chitosan-based spray. The particle size of
the different liposomal insulin formulations ranged from 0.7 up to 2.9 µm, depending on
the use of cholesterol, as this lipid increases the vesicle diameter. Insulin encapsulation
efficiency was between 37% and 84% due to the preparation technique and sonication
approach that decreased the amount of loaded drug. Through Franz diffusion cells, the
insulin dispersion and the optimized formulation expressed a prolonged release of 6 h
and up to 24 h, respectively [84]. The healing potential of insulin-containing liposomes
was evaluated by the same group, which impregnated a chitosan gel with insulin-loaded
liposomes and evaluated the clinical outcomes in non-diabetic patients [85]. Liposomal
insulin in aqueous dispersion was stable for 6 months at 4 ◦C, and its release was sustained
for 24 h. The clinical trial was coordinated in 15 patients over 8 months, in which liposomal
insulin showed wound closure 16 times faster than the control group, with less erythema
and no lowering blood sugar.
5.1.2. Solid Lipid Nanoparticles and Nanostructured Lipid Carriers
Solid lipid nanoparticles (SLN) were developed to overcome liposome limitations.
SLN consist of small carriers formed by solid lipids at body and room temperature [84].
They have been used as drug delivery platforms for topical administration due to their
biocompatibility, biodegradability, increased drug permeation through the skin, easy
preparation, and viability of large scale production [85]. Nanostructured lipid carriers
(NLC) are composed of a mixture of solid and liquid lipids. They are second generation
lipid nanoparticles generated to improve drug loading, provide prolonged drug release,
and reduce drug expulsion during storage related to solid lipid nanoparticles [86]. SLN and
NLC have been used on injured skin, as they can be formulated with non-irritant lipids [87]
and have shown sustained release of occlusive formulations, promoting drug penetration
into the skin [88]. There are no relevant studies addressing the delivery of insulin using
SLN and NLC, but both lipid nanocarriers have shown their ability to topically deliver
growth factors in a sustained and controlled manner, so they may be considered as potential
carriers for topical delivery of insulin.
Previously, Gainza et al. delivered the recombinant human epidermal growth factor
(rhEGF) in SLN and NLC to wounds, obtaining an encapsulation efficiency (EE) of SLN-
rhEGF and NLC-rhEGF of 74% and 96%, respectively. The in vitro studies were conducted
in HFF fibroblasts, HaCaT keratinocytes, and Balb/c 3T3 fibroblasts, showing the cell
proliferation effect of rhEGF compared to empty nanoparticles as well as the loading of
rhEGF into lipid nanoparticles enhanced the cell division activity compared with that
derived with cleared rhEGF (p < 0.05). The efficacy of the SLN-rhEGF and NLC-rhEGF
was probed in a full-thickness excisional wound in diabetic mice, showing improved skin
reparation. The topical administration of 10 and 20 µg of SLN-rhEGF and 10 and 20 µg of
NLC-rhEGF exhibited decreased wound area in comparison to empty lipid nanoparticles
and untreated control (p < 0.05). Furthermore, results were not significantly different
between the 10 µg and 20 µg doses [89].
In another study, the same authors evaluated the efficacy of rhEGF-loaded NLC in
a full-thickness excision wound model in pigs. The group treated with 20 µg of topically
applied rhEGF-NLC twice weekly showed a faster rate of healing, in contrast to the group
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treated with 75 µg of free rhEGF and unloaded NLC. In addition, rhEGF-loaded NLC
stimulated angiogenesis, cell migration and proliferation, and collagen deposition. No
significant levels of plasma rhEGF were found, showing evidence of no systemic absorption
having occurred [90].
5.2. Polymer Nanoparticles
Polymers are macromolecules composed of repeated monomer units, in which their
chain length depends on the number of the monomer units as well the molecular weight of
these individual monomers. The polymeric materials may come from natural and synthetic
origin being used separately or blended together for many applications, including wound
healing [91].
5.2.1. Natural Polymers
Chitosan, hyaluronic acid, cellulose, silk fibroin, gelatin, and collagen are polymers of
natural origin widely used to obtain nanocarriers. Chitosan is a chitin-derived polymer
found in the insect and crustacean exoskeleton, composed of D-glucosamine and N-acetyl-
D-glucosamine. This polysaccharide is widely used in topically applied vehicles owing to
its biocompatibility, biodegradability, microbicidal activity, low toxicity, and angiogenesis
promoter [92]. Moreover, chitosan is able to grant cell adhesion and proliferation [93] and
cell activation such as fibroblasts, leukocytes, macrophages, transforming growth factor
β1 or platelet-derived growth factor display [94]. Furthermore, chitosan-based materials
mainly show positive charge, offering mucoadhesiveness, hemorrhage control, and wound
healing stimulation [95].
Ishihara et al. studied the effect of a chitosan hydrogel on full-thickness incision
wounds on the back of mice [96]. The hydrogel was physically cross-linked using ultraviolet
light irradiation. Round-shaped wounds, with approximately 100 mm2, were performed
on the back of C57BL/6 mice with the help of a scalpel and scissors. Results showed rapid
re-epithelialization, granulation tissue development, and hemostatic effect, reaching 90%
of skin incision closure in one week, in contrast to the control group (p < 0.05). Ehterami
et al. formulated chitosan nanoparticles loaded with insulin using ionotropic gelation to be
incorporated into an electrospun poly(ε-caprolactone)/collagen. The wound dressing was
applied onto 1.5 × 1.5 cm2 full-thickness wounds on the back of Wistar rats. Their skin
backs were excised using a surgical knife, and after 2 weeks of treatment, wounds showed
both epidermal and granulation tissue formation with a scab, while control rats exhibited
approximately 60% of wound length. Furthermore, Masson’s trichrome staining results
showed foremost collagen synthesis and maturation, in contrast to the control group [97].
Although chitosan has been considered safe for wound dressing applications [98], chitosan-
based formulations are not yet acceptable for scale-up production due to limited production
reproducibility [99].
Hyaluronic acid is an important component of all connective tissues and due to its
biodegradability, moisturizing ability, cellular motility, proliferation promotion, and ability
to induce inflammatory signals [100], it is regularly used in wound healing to promote
tissue repair. Hyaluronic acid is involved in all healing phases of wounds and contributes
to the reduction of reactive oxygen species (ROS) at the wound site [101]. Hirakura et al.
developed a hyaluronic acid-based hydrogel involving nanogels formed from cholesteryl
group with pullulan content and insulin for in vitro and in vivo release studies. The
authors observed sustained and controlled release of insulin due to the crosslinking degree
without bioactivity loss [102]. Recently, Nyman and co-workers conducted a clinical
study in 10 patients to explore the outcome of intradermal hyaluronic acid administration
concerning keratinocyte stimulation and dermal re-epithelization during incisional healing.
Two volunteer groups were formed; one group was treated with hyaluronic acid injections
and the other treated with saline injections. The hyaluronic acid injections-treated group
showed 10-fold increased protein expression involved in wound healing and an increased
wound healing rate compared to saline-treated wounds. After 24 h, 90% of the hyaluronic
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acid injections-treated group exhibited restoration of the epithelium, in contrast to saline-
treated wounds that remained unchanged [103].
Alginate is a polysaccharide obtained from brown algae, consisting of different
amounts of (1–4)-linked β-D-mannuronic acid (M) and α-L-guluronic acid (G). These G
residues favor gelation in the presence of divalent ions, enabling the formation of nanopar-
ticles. Alginate and its salts present hemostatic and regenerative characteristics that have
been used for wound dressings, stimulating cell migration, enhancing angiogenesis, and
decreasing proinflammatory cytokine levels in chronic wounds. Due to their hydrophilic
nature, alginate dressings maintain a moist environment, absorbing wound exudate and
restricting bacterial infections at the wound site [104]. In 2010, Borselli et al. formulated
an injectable alginate gel containing both insulin-like growth factor-1 (IGF-1) and VEGF
and delivered it in ischemic mice. Only IGF-1 treatment reduced the apoptosis process
and increased cell activation and proliferation, leading to the considerable reconstruction
of muscle fibers at the wound site. Nevertheless, IGF-1 showed an in vitro release of ap-
proximately 80% in the first 24 h, in contrast to VEGF, which presented a sustained release
profile showing an in vitro release of approximately 40% in the first 24 h [105]. Although
natural polymers offer biocompatibility and biodegradability, only with synthetic polymers
is there structure control, providing tailorable properties.
5.2.2. Synthetic Polymers
Polycaprolactone (PCL), polyethylene glycol (PEG), poly(lactic acid) (PLA),
poly(glycolic acid) (PGA), and poly(lactic-co-glycolic acid) (PLGA) are synthetic poly-
mers that have been used in regenerative medicine [106]. PLGA, a copolymer formed by
glycolic and lactic acid has been used to produce nanoparticles due to its biodegradability
and sustained release properties [107–109]. During its degradation, lactate is released,
promoting the formation of new blood vessels [108].
Hrynyk et al. encapsulated crystallized insulin in PLGA carriers for topical adminis-
tration to improve wound healing. Insulin biological activity showed activation of insulin
receptors in cell culture-based phosphorylated AKT and triggered HaCaT cell migration
using a cell scratch assay over a period of 3 weeks, versus the insulin-free control [109].
Later, in 2012, Hrynyk et al. encapsulated insulin into PLGA carriers to be incorporated into
an alginate-containing PEG sponge. This sponge dressing formed a hydrogel, providing
protection and a moist environment needed for the wound healing process. Sustained
release profile was maintained up to 21 days, demonstrating migration rates of human
epidermal keratinocytes for 10 days, compared to 10−7 M insulin solution [110]. In 2018,
Abdelkader et al. considered the delivery of insulin-loaded PLGA nanoparticles with
varying amounts of PEG embedded in a PVA-borate hydrogel. Although the authors
found that variation of PEG concentration had low impact on wound closure rate, they
observed faster cell proliferation on human fibroblasts (Hs27) and keratinocytes (HaCaT)
in cell scratch assay following the addition of nanoencapsulated insulin, compared to
free insulin [111]. In another approach, insulin encapsulation in PLGA nanoparticles was
developed by a modified double emulsion solvent evaporation technique and incorporated
in a poly(vinyl alcohol)-borate hydrogel to evaluate wound healing in healthy and diabetic
rats. The insulin-loaded PLGA nanoparticles had 34 µg/mg of insulin and a diameter of
203 nm [74]. Both healthy and diabetic mice treated with insulin-loaded PLGA nanopar-
ticles incorporated into the PVA-borate hydrogel exhibited faster wound recovery than
healthy and diabetic mice receiving free insulin incorporated into the hydrogel (p < 0.001).
After 10 days, the deviation between the percentage wound injury index of unloaded in-
sulin was 12% in comparison to the control, whereas the deviation between the percentage
wound injury index of insulin-PLGA nanoparticles was 30% in contrast to control.
5.3. Inorganic Nanoparticles
The application of inorganic nanoparticles for topical insulin delivery is neglectable.
However, in this section, different inorganic nanoparticles are addressed with a foreseen
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potential for that purpose. Metal nanoparticles are submicron particles of metallic (silver,
gold, cerium, or titanium) and magnetic (iron oxide) origin [112]. Silver nanoparticles are
easily obtained by safe and inexpensive methods, and can be used in dressings, exhibiting
antibacterial activity against a wide range of bacteria without developing microbial resis-
tance [113]. Both sulfadiazine and silver nitrate have been shown to attenuate mast cell
infiltration as well as cytokine and lymphocyte levels [114]. In 2007, Tian and co-workers
subjected BALB/C mice to deep partial thickness thermal burns to evaluate healing time
using silver dressings. BALB/C mice burns treated with silver nanoparticles healed in
27 days compared to mice treated with silver sulfadiazine and saline taking an average
of 37 and 35 days to heal the wounds, respectively [115]. Liu et al. (2010), conducted
a study to evaluate the effect of silver nanoparticles and silver sulfadiazine on dermal
contraction, and epidermal re-epithelialization in a full-thickness excisional wound model
on mice. AgNPs-treated wounds revealed faster closure, a higher rate of fibroblast differ-
entiation into myofibroblasts, and increased proliferation and deposition of keratinocytes
compared to silver sulfadiazine-treated wounds [116]. Moreover, silver nanoparticles are
highly reactive due to negative surface charge, providing a strong interaction with amine
or thiol groups [117]. Kaur et al. coated silver nanoparticles with insulin for the treatment
of diabetic wounds. The study was performed on human epidermal keratinocyte cells
and male Wistar rats in which the authors found that pro-inflammatory (TNFα, IL-6) and
anti-inflammatory (IL-10) cytokines levels were regulated in the wound, contributing to
rapid healing [118].
In 2010, Rakhmetova and co-workers described a study of an ointment containing
copper nanoparticles for wound healing in mice. Copper nanoparticles were modified
using oxygen vapors, air, and water and developed by condensation at high temperatures.
The authors observed that the ointment containing 100 nm diameter copper nanoparti-
cles, modified with O2 and having 95% of crystalline copper content, increased wound
remodeling, compared to the ointment without copper nanoparticles [119].
Chigurupati et al. observed that the topical application of cerium oxide nanoparticles
(nanoceria) enhanced the healing of full-thickness dermal wounds. Cell proliferation was
determined in human keratinocyte cells and mouse fibroblasts, in which an increased
cell proliferation rate was found in the presence of 1 and 10 µM nanoceria. The authors
also found that the nanoceria decreased oxidative stress, allowing regenerative tissue
preservation, thus increasing the proliferation of fibroblasts, keratinocytes, and endothelial
cells [120].
In 2014, Sankar and collaborators prepared, by green synthesis, titanium dioxide
nanoparticles (TiO2.NPs) from the leaf extract of Origanum vulgare. Healing activity was
examined using a full-thickness excision wound model in Albino rats. Wound contraction
was measured by microscopic examination of the granulation tissue and by evaluating the
protein expression. Animals treated with topical TiO2.NPs showed no signs of hemorrhage
or infection, and wound retraction was observed by day 4. On the 12th day, SDS-PAGE
analysis revealed differentially expressed proteins on TiO2.NPs treated animals, showing
increased density on the 25, 55, 75, and 150 kD bands, in contrast with the control group.
The rats treated with topical saline solution following histopathological analysis showed
low fibroblast levels and collagen deposition when compared to TiO2.NPs-treated animals,
demonstrating the therapeutic efficacy of the nanoparticles [121].
Gold nanoparticles are also effective for wound care, as gold is a reliable drug carrier.
Taking advantage of the specific gene expression for skin repair, Randeria et al. associated
gold nanoparticles with siRNA-based spherical nucleic acids (SNAs) to inhibit ganglioside-
monosialic acid 3 synthetase (GM3S) overexpression, restricting insulin resistance and
hindering wound healing in diabetic patients. The study conducted in cultured mouse
keratinocytes showed stimulation of both insulin and insulin-like growth factor-1 (IGF1) re-
ceptors under normal and hyperglycemic conditions, as well as an increase of keratinocyte
migration and proliferation, in contrast to control. Topical administration of spherical
nucleic acids conjugated to AuNPs in full-thickness wounds in diabetic mice caused more
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than 80% reduction in GM3S synthesis at the wound site, and within 12 days diabetic
wounds were completely closed, whereas only half of the control group wounds exhibited
recovery [122]. Currently, gold nanoparticles have been produced using plants with an-
tidiabetic properties. Ponnanikajamideen et al. developed, through green synthesis, gold
nanoparticles from the Chamaecostus cuspidatus insulin plant to analyze the wound healing
and hypoglycemic effect. Male Wistar rats were divided into four different groups for the
wound-healing test: control double distilled water, vehicle control H2O, green synthesized
Gold NPs, and plant extract. After the 4th week of post wounding, the authors observed
that gold NPs and plant extract groups exhibited a higher healing rate and a prolonged
anti-inflammatory and antioxidant effect over time, when compared to both control groups
treated with double distilled water and vehicle control H2O [123].
Silica or silicon dioxide nanoparticles have been used for theragnostic applications due
to their versatile properties such as easy production, adjustment, low toxicity, molecular
stability, and targeted delivery [124]. Quignard and co-workers analyzed the wound
healing process, by applying 50 and 100 µM of silica nanoparticles in an in vitro wound
healing assay using human dermal fibroblasts (CCD-25SK). After 3 days of treatment, the
authors observed that both concentrations stimulated cell viability and proliferation versus
the control group (p < 0.05) [125].
Table 2. Brief summary of nanoparticles encapsulating insulin used for wound healing applications.
Type of
Nanoparticles Material Size (nm) PdI
Zeta Potential









caprolactone)/collagen 256 0.23 17.89 L929 cells C57BL/6 mice ~63 [97]
PLGA, PEG 297 0.15 −3.94 HaCat, human fibroblasts - - [110]
Inorganic
nanoparticles Silver 10 - -
Mouse embryo fibroblast cell
line (BALB/3T3; clone A31)
C57BL/6N
mice ~31 [116]
Silver 42 - −15.1 Human epidermalkeratinocyte cells (HEKa) Wistar rats ~73 [118]
Copper 119 - - - Mice of theSHK line ~52 [119]
Nanoceria 5 - - HMEC-1 cells C57BL/6 mice - [120]
Titanium dioxide 341 - −27.3 - Wistar Albinorats 94 [121]
Gold 50 - - - Wistar rats 97 [126]
Silica 10 - −30 to +23 CCD-25SK cells - - [125]
6. Pipeline Products
Despite the many studies over the years suggesting the potential benefits of insulin-
loaded nanocarrier systems for wound healing, no products are commercially available
in the market. This is due to the need for further studies to gain more knowledge about
safety and effectiveness of these topical delivery systems [127]. Notwithstanding, several
commercially available products have emerged with the use of growth factors for wound
healing, thus insulin may also follow this path.
Regranex gel (Healthpoint Biotherapeutics, Fort Worth, TX, USA) contains recombi-
nant human platelet-derived growth factor. Regranex has been approved by the FDA for
the prevention of lower-limb amputations in the cases of diabetic foot ulcers (DFUs) [128].
Patients with diabetic wounds treated with topical platelet-derived growth factors experi-
enced around a 40% wound closure increase, compared to control group [129]. Fiblast®
Spray commercialized in Japan consists of recombinant fibroblast growth factor (rhbFGF)
for the treatment of leg ulcers and burns [130].
Hayashida et al. showed that pediatric patients suffering from second-degree burns
and treated with bFGF had decreased scarring and rapid healing, compared with the
controls [131]. Other commercially available approaches to tissue regeneration are Easyef®,
Regen-D™ 150, and Heberprot-P®. All of these approaches are based on recombinant hu-
man epidermal growth factor (rhEGF), effective in treating DFUs, pressure ulcers, vascular
ulcers, and chronic leg ulcers. In particular, Regen-D™ 150 is a gel composed of 150 µg/g
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rhEGF, being topically applied to DFUs twice a day [70]. Heberprot-P® includes 75 µg
rhEGF, being injected to the wound bed three times per week. However, additional studies
are needed to compare the safety and efficacy of rhEGF with other growth factors [132].
Johnson & Johnson has developed Promogran for topical wound therapy in the form
of sterile, lyophilized, oxidized regenerated cellulose and collagen, deactivating the wound
bed proteases and protecting the growth factors that are present in the wounds. Veves
et al. conducted a randomized, prospective, controlled clinical trial, determining that
Promogran was more effective in treating DFUs of less than 6 months compared with the
wet gauze dressing used [133]. Recently, homologous platelet-rich plasma (PRP) was used
for the treatment of chronic wounds, as thrombin activates platelets releasing mitogenic
and chemotactic factors throughout the wound healing process. For this reason, Nuo
Therapeutics, Inc. (Gaithersburg, MD, USA) developed the AutoloGel™ indicated for the
treatment of chronic wounds being topically applied up to twice a week [134]. Shortly after,
the same company launched Aurix™, a hematogel obtained from the patient’s own plasma
and platelets to stimulate skin recovery [135].
In 2016, the Praxis Biopharma Research Institute (Álava, Spain) patented a nanoparti-
cle delivery system for wound healing with SLN and NLC loading epidermal growth factor
(rhEGF) and cathelicidin antimicrobial LL37 peptide, present at deficient levels in chronic
ulcers. The researchers found a sustained release of the loaded rhEGF and a higher in vitro
proliferation rate of fibroblasts than unloaded rhEGF [136]. Among the several products
considered for topical administration, silver nanoparticles are often used in creams, gels,
or dressings due to their effectiveness in hospital-acquired infections caused by antibiotic
resistant bacteria, and local therapy of infected wounds [137]. Moreover, AgNPs have
anti-inflammatory properties and collagen control regulation, inducing its proper arrange-
ment during wound closure. Although the mechanism is still unknown by which silver
nanoparticles act on collagen, in several clinical cases where AgNPs-containing dressings
were studied, results suggest that AgNPs improved epithelial regeneration, compared with
current commercially available wound therapy dressings [138].
7. Toxicity Concerns
Nanoparticles for drug delivery offer protection of the active compounds, biodegrad-
ability, and sustained release, providing treatments that are safer and more efficient [139].
However, their size, high surface area, surface reactivity, form, chemical composition, and
time of residence are the physicochemical features that can drive nanoparticles to present
toxicity. Nanometer-sized particles have strong exposure to fluids and tissues due to their
larger contact surface and greater biological reactivity, possibly affecting the regulation cell
mechanisms [140]. Schneider et al. reported that it is necessary to address the nanoparticles
size and their mechanism of action on the skin for wound healing [141]. The resulting
by-products may accumulate in cells inducing transmutations, triggering cell hemostasis
disturbance and oxidative stress formation [142].
Upton et al. conducted a clinical trial composed of 30 patients suffering from pressure
ulcers, diabetic foot ulcers, and venous leg ulcers on which they only observed two cases
of adverse events associated with insulin-like growth factor (IGF) and epidermal growth
factor (EGF) when 132.5 µg of vitronectin was topically applied. In one case, burning
after dressing application was reported, and in the other, an itching sensation at the ulcer
site was reported [143]. Dhall et al. also observed in vivo that topical insulin-loaded
PLGA microparticles delivery decreases levels of reactive oxygen species. The activity of
superoxide dismutase (SOD) was measured at 450 nm by the reduction of tetrazolium salts.
The authors found that insulin therapy decreased SOD and H2O2 levels during the first
3 days of healing [35].
The biodegradable polymeric nanoparticles, such as poly-ε-caprolacton (PCL), PLA,
and PLGA, have been preferred as drug carriers due to their biocompatibility, biodegra-
dation, non-immunogenicity, and non-toxicity [35]. Several authors have expressed the
safety of gold nanoparticles at the cellular level, while others have indicated DNA damage
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during cell division and immune system activity, demonstrated by both in vitro and in vivo
analysis [144]. Agryria, a bluish-gray tinge in the skin, as well as cellular toxicity and
impaired fibroblast repairment processes have been correlated with the continued use of
silver nanoparticles [145]. Nevertheless, the toxicity of AgNPs can be decreased by using
green synthesis with natural capping agents to remove hazardous chemicals [146]. In the
case of silica nanoparticles, Ryu et al. showed that percutaneous application of 20 nm
silica particles for 3 months in Sprague Dawley rats did not cause skin or internal organ
toxicity [147]. Another example is impaired cell function on human dermal fibroblasts
caused by titanium dioxide nanoparticles. Pan et al. formulated TiO2.NPs coated with
polymer molecules, namely proanthocyanidins/poly(methyl-vinylether/maleic acid) (30%
w/w) and triethoxysilylethyl poly(dimethylsiloxyethyldimethicone) (5% w/w). Due to this
process of coating, enhanced human dermal fibroblasts protection and reduced reactive
oxygen species was observed through flow cytometry [148].
8. Conclusions
Wound healing is a biological process resulting from the restoration of the integrity of
the skin barrier. The use of nanotechnology to accomplish topical delivery of insulin has
demonstrated to be effective for wound healing. The use of nanoparticles to deliver insulin
to wounds increases their stability, while providing adhesion to the mucosal surfaces and
preserving the sustained release enabling safer treatments. Insulin has been shown to have
the ability to reduce inflammation, decrease oxidative damage, promote tissue neogenesis,
as well as promote collagen deposition and maturation, at a lower cost than other repairing
growth factors. Despite promising studies developed so far, no formulation has yet been
launched on the market. Additional studies are needed for a better understanding of
the bioactivity and toxicity of nanoparticles applied to wounds and to ensure insulin
bioavailability in the skin, in order to achieve a safe and effective insulin nanotechnology
treatment for wound care. It is expected that this review may be a contribution to leverage
the development of therapeutically effective and safe nanocarrier systems for topical
insulin delivery.
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